These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 10359733)

  • 1. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience.
    McClure MW; Berkowitz SD; Sparapani R; Tuttle R; Kleiman NS; Berdan LG; Lincoff AM; Deckers J; Diaz R; Karsch KR; Gretler D; Kitt M; Simoons M; Topol EJ; Califf RM; Harrington RA
    Circulation; 1999 Jun; 99(22):2892-900. PubMed ID: 10359733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.
    Hasdai D; Holmes DR; Criger DA; Topol EJ; Califf RM; Wilcox RG; Paolasso E; Simoons M; Deckers J; Harrington RA
    Am Heart J; 2000 Mar; 139(3):454-60. PubMed ID: 10689260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
    Mahaffey KW; Harrington RA; Simoons ML; Granger CB; Graffagnino C; Alberts MJ; Laskowitz DT; Miller JM; Sloan MA; Berdan LG; MacAulay CM; Lincoff AM; Deckers J; Topol EJ; Califf RM
    Circulation; 1999 May; 99(18):2371-7. PubMed ID: 10318656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Lauer MA; Houghtaling PL; Peterson JG; Granger CB; Bhatt DL; Sapp SK; Simoons ML; Harrington RA; Topol EJ; Lincoff AM;
    Circulation; 2001 Dec; 104(23):2772-7. PubMed ID: 11733393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
    Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators
    N Engl J Med; 1998 Aug; 339(7):436-43. PubMed ID: 9705684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Labinaz M; Kilaru R; Pieper K; Marso SP; Kitt MM; Simoons ML; Califf RM; Topol EJ; Armstrong PW; Harrington RA
    Circulation; 2002 Jan; 105(3):322-7. PubMed ID: 11804987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.
    Akkerhuis KM; Maas AC; Klootwijk PA; Krucoff MW; Meij S; Califf RM; Simoons ML
    J Electrocardiol; 2000 Apr; 33(2):127-36. PubMed ID: 10819406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Lincoff AM; Harrington RA; Califf RM; Hochman JS; Guerci AD; Ohman EM; Pepine CJ; Kopecky SL; Kleiman NS; Pacchiana CM; Berdan LG; Kitt MM; Simoons ML; Topol EJ
    Circulation; 2000 Sep; 102(10):1093-100. PubMed ID: 10973836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of patients with non-ST-segment elevation acute coronary syndromes: insights from the PURSUIT trial.
    Fintel DJ; Ledley GS
    Clin Cardiol; 2000 Sep; 23 Suppl 5(Suppl 5):V1-12. PubMed ID: 11019716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
    Giugliano RP; Newby LK; Harrington RA; Gibson CM; Van de Werf F; Armstrong P; Montalescot G; Gilbert J; Strony JT; Califf RM; Braunwald E;
    Am Heart J; 2005 Jun; 149(6):994-1002. PubMed ID: 15976780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Glycoprotein IIb/IIIa antagonist eptifibatide in acute coronary syndrome without elevation of ST segment].
    Mazaev AA; Naĭmushin IaA; Ruda MIa
    Kardiologiia; 2006; 46(3):49-55. PubMed ID: 16710256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of eptifibatide in patients undergoing percutaneous coronary intervention.
    Zeymer U
    Expert Opin Pharmacother; 2007 Jun; 8(8):1147-54. PubMed ID: 17516878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy.
    Dyke CM; Bhatia D; Lorenz TJ; Marso SP; Tardiff BE; Hogeboom C; Harrington RA
    Ann Thorac Surg; 2000 Sep; 70(3):866-71; discussion 871-2. PubMed ID: 11016325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes.
    Srichai MB; Jaber WA; Prior DL; Marso SP; Houghtaling PL; Menon V; Simoons ML; Harrington RA; Hochman JS;
    Am Heart J; 2004 Jan; 147(1):84-90. PubMed ID: 14691424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
    Granada JF; Kleiman NS
    Am J Cardiovasc Drugs; 2004; 4(1):31-41. PubMed ID: 14967064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
    Goa KL; Noble S
    Drugs; 1999 Mar; 57(3):439-62. PubMed ID: 10193692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
    Silva MA; Gandhi PJ
    J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
    Harrington RA
    Am J Cardiol; 1997 Aug; 80(4A):34B-38B. PubMed ID: 9291244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial.
    Fitchett DH; Langer A; Armstrong PW; Tan M; Mendelsohn A; Goodman SG;
    Am Heart J; 2006 Feb; 151(2):373-9. PubMed ID: 16442903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.